LATIA BUTTS: Open Payments
NPI 1164731931 · GRENADA, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,229 in 107 payments from 28 companies in 2025. Trend: 2023 $2,075 · 2024 $1,878 · 2025 $2,229
Food & beverage: $2,213Education: $16
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 13 | $221 |
| Merck Sharp & Dohme LLC | 8 | $207 |
| Novartis Pharmaceuticals Corporation | 9 | $182 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $180 |
| Gilead Sciences, Inc. | 6 | $179 |
| Lilly USA, LLC | 6 | $148 |
| Celgene Corporation | 7 | $145 |
| Daiichi Sankyo Inc. | 6 | $144 |
| PFIZER INC. | 7 | $99 |
| ARRAY BIOPHARMA INC | 4 | $77 |
Products named: KEYTRUDA, Trodelvy, REBLOZYL, Enhertu, OPDIVO, VERZENIO, BRAFTOVI, SCEMBLIX.
Industry payments across MS — which companies pay providers there.
